Skip to content

Duration of Infusion Set Function: Quick-Set Teflon Catheter Versus Sure-T Steel Infusion Set Catheter

Duration of Infusion Set Function: A Study Comparing the Quick-Set Teflon Catheter vs Sure-T Steel Infusion Set Catheter

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01288729
Enrollment
20
Registered
2011-02-02
Start date
2011-01-31
Completion date
2011-07-31
Last updated
2017-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

This is an open-label cross over study looking to compare the length of infusion set wear between a teflon catheter (Quick-Set) or a steel (Sure-T) catheter.

Detailed description

Currently infusion sets are approved for 2-3 days of wear. In this study subjects will wear each infusion set for up to 7 days or until the infusion set fails. Subjects will alternate between wearing the Quick-Set Teflon catheter and the Sure-T steel catheter each week. They will wear each infusion set twice. For the study, subjects will be provided with an investigational Medtronic Real-Time Continuous Glucose Monitor (CGM) Enlite Sensor/Serter to help identify, serious hyperglycemia or hypoglycemia during the study. This sensor is not yet FDA approved, but is similar to commercially available sensors. If the sensor detects a high or low glucose, subject must obtain a fingerstick glucose to confirm the result. In the study, all insulin dose and other treatment decisions will be made using glucose meter results, and will not be based on sensor results. Subjects will be instructed on how to identify infusion set failures. Infusion set failure are defined as: 1) Blood ketones greater than 0.6 mmol/L, 2) Evidence of infection at the infusion site (such as redness of more than 4 mm), or 3) Blood glucose that does not decrease by at least 50 mg/dL within 1 hour of a correction bolus to treat a blood glucose greater than 300 mg/dL. Subjects will follow-up weekly in one of our test centers for a total of five visits. At home subjects will be asked to keep a log recording measurements of redness and induration at the infusion site when it is changed prior to the study visit.

Interventions

DEVICESure-T Steel Infusion Set Catheter

Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time

DEVICEQuick-Set Teflon Catheter

Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time

Sponsors

Stanford University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of type 1 diabetes for at least one year and using an insulin pump for at least 3 months * The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed. * Age 12 to 45 years * For females, not currently known to be pregnant * An understanding of and willingness to follow the protocol and sign the informed consent * Hemoglobin A1c level less than or equal to 10% * Medtronic Continuous subcutaneous insulin infusion pump * Must be able to understand spoken or written English

Exclusion criteria

* Diabetic ketoacidosis in the past 6 months * Severe hypoglycemia resulting in seizure or loss of consciousness in the 6 months prior to enrollment * Current treatment for a seizure disorder * Cystic fibrosis * Active infection * A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples: * Inpatient psychiatric treatment in the past 6 months for either the subject or the subject's primary care giver (i.e., parent or guardian) * Presence of a known adrenal disorder * If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study * Abuse of alcohol

Design outcomes

Primary

MeasureTime frameDescription
Length of Wear of Infusion Site5 weeksComparison of the length of wear (hours) of Sure-T Steel Infusion Set Catheter versus Quick-Set Teflon Catheter. Infusion sets are currently approved for wear 2-3 days (24-72 hours). Participants wore each set for up to 7 days twice. Outcome measure is presented according to the intervention (Steel or Teflon catheter).

Participant flow

Participants by arm

ArmCount
Group 1 - Steel Cathetar, Then Teflon
Participants will alternate between wearing the Sure-T Steel Infusion Set Catheter for 7 days, then the Quick-Set Teflon for 7 days.They will wear each set twice starting with the Sure-T Steel Infusion Set.
10
Group 2 - Teflon Cathetar, the Steel
Participants will alternate between wearing the Quick-Set Teflon catheter for 7 days, then the Quick-Set Teflon for 7 days. They will wear each set twice starting with the Quick-Set Teflon set.
10
Total20

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject10

Baseline characteristics

CharacteristicGroup 1 - Steel Cathetar, Then TeflonGroup 2 - Teflon Cathetar, the SteelTotal
Age, Continuous22.3 years
STANDARD_DEVIATION 8.8
22.3 years
STANDARD_DEVIATION 8.8
22.3 years
STANDARD_DEVIATION 8.8
Gender
Female
4 Participants4 Participants8 Participants
Gender
Male
6 Participants6 Participants12 Participants
Region of Enrollment
United States
10 participants10 participants20 participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
7 / 207 / 20
serious
Total, serious adverse events
0 / 200 / 20

Outcome results

Primary

Length of Wear of Infusion Site

Comparison of the length of wear (hours) of Sure-T Steel Infusion Set Catheter versus Quick-Set Teflon Catheter. Infusion sets are currently approved for wear 2-3 days (24-72 hours). Participants wore each set for up to 7 days twice. Outcome measure is presented according to the intervention (Steel or Teflon catheter).

Time frame: 5 weeks

Population: Participants with available data were analyzed.

ArmMeasureValue (MEDIAN)
Sure-T Steel Infusion Set CatheterLength of Wear of Infusion Site137 hours
Quick-Set Teflon CatheterLength of Wear of Infusion Site145 hours

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026